Home World News FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma World News FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma By Ogkologos - July 22, 2026 180 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-022 study Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR A vision for the next decade of UK life sciences July 21, 2021 COVID-19 Vaccine Myth Busters January 28, 2021 FDA Approves Revumenib for Relapsed or Refractory Acute Leukaemia with a... December 10, 2024 Grandparents of children with cancer: “I would never want to go... September 1, 2020 Load more HOT NEWS Green Beret With Lung Cancer Surprised With Hundreds Of ‘Thank You’... A urine test for bladder cancer: What’s the latest? Ground-breaking trial pilots new tests to detect lung cancer earlier For Hairy Cell Leukemia, Drug Combination Leads to Long-Lasting Remissions